Exploring the path to polio eradication: insights from consecutive seroprevalence surveys among Pakistani children

Front Public Health. 2024 Mar 27:12:1384410. doi: 10.3389/fpubh.2024.1384410. eCollection 2024.

Abstract

Introduction: After trivalent oral poliovirus vaccine (tOPV) cessation, Pakistan has maintained immunity to type 2 poliovirus by administering inactivated polio vaccine (IPV) in routine immunization, alongside monovalent OPV type 2 (mOPV2) and IPV in supplementary immunization activities (SIAs). This study assesses the change in poliovirus type 2 immunity after tOPV withdrawal and due to SIAs with mOPV2 and IPV among children aged 6-11 months.

Methods: Three cross-sectional sequential serological surveys were conducted in 12 polio high-risk areas of Pakistan. 25 clusters from each geographical stratum were selected utilizing probability proportional to size.

Results: Seroprevalence of type 2 poliovirus was 49%, with significant variation observed among surveyed areas; <30% in Pishin, >80% in Killa Abdullah, Mardan & Swabi, and Rawalpindi. SIAs with IPV improved immunity from 38 to 57% in Karachi and 60 to 88% in Khyber. SIAs with IPV following mOPV2 improved immunity from 62 to 65% in Killa Abdullah, and combined mOPV2 and IPV SIAs in Pishin improved immunity from 28 to 89%. Results also reflected that immunity rates for serotypes 1 and 3 were consistently above 90% during all three phases and across all geographical areas.

Conclusion: The study findings highlight the importance of implementing effective vaccination strategies to prevent the re-emergence of poliovirus. Moreover, the results provide crucial information for policymakers working toward achieving global polio eradication.

Keywords: Pakistan; eradication; poliovirus; seroprevalence; type 2 immunity.

MeSH terms

  • Child
  • Cross-Sectional Studies
  • Humans
  • Pakistan / epidemiology
  • Poliomyelitis* / epidemiology
  • Poliomyelitis* / prevention & control
  • Poliovirus Vaccine, Inactivated
  • Poliovirus Vaccine, Oral
  • Poliovirus*
  • Seroepidemiologic Studies

Substances

  • Poliovirus Vaccine, Oral
  • Poliovirus Vaccine, Inactivated

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was supported by the Bill & Melinda Gates Foundation (grant number OPP1156736).